You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1387-ESGO Patients with minimal residual disease at upfront debulking surgery have similar survival outcome than patients with complete cytorreduction after neoadjuvant chemotherapy

Article metrics

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-1387-ESGO Patients with minimal residual disease at upfront debulking surgery have similar survival outcome than patients with complete cytorreduction after neoadjuvant chemotherapy
Free

 

Online download statistics by month:

Online download statistics by month: October 2022 to April 2024

AbstractFullPdf
Oct 20221203
Nov 20223005
Dec 20225109
Jan 20231601
Feb 20232002
Mar 20232000
Apr 20232200
May 20232600
Jun 20231201
Jul 20231605
Aug 20231004
Sep 20231600
Oct 20231402
Nov 20231801
Dec 20232303
Jan 20241803
Feb 20241604
Mar 20241803
Apr 2024401
Total362047